Replies to post #71784 on Innovation Pharmaceuticals Inc (IPIX)

[TheMonolith]

CTIX was on the radar of a lot of heavy hitters just waiting to pounce at the right moment. Now, the fear of being left behind is driving action.

[thefamilyman]

The buying is "obviously" coming from the Big Pharma that Leo is currently in negotiations with on B. They "obviously" want to be holding ~10% of the outstanding shares before any deal announcement is made. Of course this is "obviously" JMHO... :-D

cabel said...

I ask,... where is all this buying coming from,..?

Where is all that money coming from,... $4.5 million dollars,.. lots of buys for 10-15 thousand shares at a time,... some for much more.

I am hoping one day we will discover where all this buying came from that brought us from $1.80 to $3.00 in such a short time.

Is there a deal that someone knows about,... a leak from the trial results,...?

[TOB]

I think that is an excellent question.

We are looking at another 1 million plus day,... probably 1.5 million again.

That is impressive buying especially at the all time high of around $3.00.

I ask,... where is all this buying coming from,..? -cabel

The buying appetite for CTIX is impressive at this level.

This pre-catalyst rally is a beautiful thing to behold. I think the price action has drawn new eyes and money to CTIX which have concluded that the upside potential outweighs the odds of waiting for a minor pull-back.

Today's price action at psych-resistance looks quite similar to the battle at real resistance on 9/17/14, but two things stand out:

1. Although that one resolved with a pull-back, the CTIX share price has rallied significantly from that day's high.

2. While this last rally wave looks large and sellers where expected, the percentage rally increase is still quite modest considering the powerful catalyst approaching.

Compare with 2012 for reference. That rally was far greater in percentage terms and there were no upcoming catalysts. Brilacidin was not yet even acquired.

Here CTIX is only about 50 cents over the 2012 high, yet with a major catalyst with a new drug approaching, and the original Kevetrin vastly ahead of where it was in 2012. An almost certain Phase 1 Clinical Trial success.

Add to this smaller catalysts that are expected, three additional clinical trial starts for Brilacidin-OM, Prurisol and Kevetrin, not to mention up-listing plans, and one could well come to the conclusion that CTIX remains deeply undervalued at just 50 cents above the 2012 high.


.